Optimus pharma - Latest News Update, Information, Photos & Videos on Optimus pharma at Lokmat Times

Optimus Pharma has announced today that it has received DCGI approval for its Anti-Parkinson's drug Safinamide. Safinamide is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes.The burdens of Parkinson's Disease (PD) are undeniably serious and increasing while various unmet needs remain, especially the absence of disease-modifying therapies, especially in Indian Market. Optimus believes Safinamide will give an additional option to healthcare professionals in the treatment of Parkinson's and improve the quality of life of millions who are affected by Parkinson's disease. A homegrown generic version of Safinamide developed by Optimus will assist in delivering robust treatment for Parkinson's diseases in India with very high affordability and accessibility.Parkinson's DiseaseParkinson's disease (PD) is one of the most common neurologic disorders, affecting approximately 1 per cent of individuals older than 60 years and causing progressive disability that can be slowed but not halted, by treatment. Parkinson's disease is a movement disorder that causes involuntary movements and rigidity, as well as abnormal walking and posture. It is caused by an imbalance between two chemicals that transmit signals from the brain, dopamine, and acetylcholine.Disclaimer:Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be "forward-looking statements" within the meng of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.References:****This story is provided by PNN. will not be responsible in any way for the content of this article. (/PNN)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Lok Sabha Election 2024

Ram Navami 2024

Dubai Rains

Maharashtra Lok Sabha Election

IPL 2024

Salman Khan

Optimus PharmaFOLLOW

Optimus pharma, Latest News

Business :Optimus Pharma granted permission for restricted use under emergency situation from the DCGI for its COVID-19 pill MOLNUPIRAVIR

Hyderabad, Optimus Pharma announced launching of their front line COVID-19 medication Molnupiravir in the Indian market, as they have received permission the restricted emergency use for Covid-19 drug. ...

Business :Optimus announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir conducted in India

Optimus Pharma on Sunday submitted the interim result of Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild Covid-19 patients. ...

Business :Drugs manufacturer from Hyderabad on overdrive

Optimus Pharma on Tuesday received DCGI nod for conducting Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild and Moderate Covid-19 symptoms. ...

Business :Optimus Pharma launched a new Anti-Parkinson's Drug in India

Optimus Pharma has announced today that it has received DCGI approval for its Anti-Parkinson's drug Safinamide. Safinamide is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episode ...